TrumpRx Adds Nine Major Drugmakers to Discounted Prescription Program

According to details released by the White House, several high-cost and widely prescribed medications will be offered at reduced rates.

The agreements bring Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi onto the TrumpRx platform, significantly expanding the range of discounted drugs available to U.S. patients.

According to details released by the White House, several high-cost and widely prescribed medications will be offered at reduced rates.

Boehringer Ingelheim’s Jentadeuto for type 2 diabetes will be listed at $55, while Bristol Myers Squibb’s HIV medication Reyataz will be priced at $217. Genentech’s flu treatment Xofluza will be available for $50, and Amgen’s cholesterol-lowering drug Repatha will be offered at $239.

Additional listings include Gilead Sciences’ hepatitis C drug Epclusa at $2,425, Merck’s diabetes medication Januvia at $100, and Novartis’ multiple sclerosis therapy Mayzent at $1,137. Sanofi will reduce the price of its blood thinner Plavix to $16 and list its insulin products on TrumpRx at $35 per month’s supply. GSK will also cut prices across its inhaler portfolio, including Advair Diskus 500/50, which will be offered at $89.

Beyond pricing agreements, the participating drugmakers have committed to collective investments of at least $150 billion in U.S. manufacturing. The companies will also donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve, a federal initiative designed to strengthen domestic supply chains during emergencies and reduce reliance on foreign sources.

The announcement follows earlier policy-linked agreements between the Trump administration and pharmaceutical companies. Earlier this month, Boehringer Ingelheim confirmed a separate deal with the administration that exempts the company from potential Section 232 tariffs. Under that agreement, the company plans to invest $10 billion in U.S. research, development, and manufacturing through 2028, including $1 billion in capital expenditures.

TrumpRx was launched in September and has steadily expanded its partnerships. In November, the White House announced agreements with Eli Lilly and Novo Nordisk to offer GLP-1 drugs such as Zepbound, Ozempic, and Wegovy at discounted rates through the platform. Pfizer had previously joined the program, with its participation linked to temporary relief from tariffs on overseas-manufactured drugs.

Stay tuned for more such updates on Digital Health News